The approval is based on a clinical trial which showed that after an average of 30 months, the survival rate was higher in the Vyndaqel group.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.